Celiac Disease Market Analysis 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Statistics, Revenue, Prevalence, Medication, Treatment Market and Companies by DelveInsight
"Celiac Disease Market"
Celiac Disease Companies working in the treatment market are Sanofi (Provention Bio), Zedira, Dr. Falk Pharma, Takeda, ImmunoGenX, Provention Bio, Sanofi, Topas Therapeutics GmbH, Pfizer, 9 Meters Biopharma, Inc., ChemoCentryx, BioLineRx, Ltd., and others
(Albany, USA) DelveInsight's 'Celiac Disease Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Celiac Disease, historical and forecasted epidemiology as well as the Celiac Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The Celiac Disease market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Celiac Disease market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Celiac Disease treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Celiac Disease market.
To Know in detail about the Celiac Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here;
Some of the key facts of the Celiac Disease Market Report:
The Celiac Disease market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
In May 2025, Teva Pharmaceutical Industries, Ltd. (NYSE and TASE: TEVA) today announced that the US Food and Drug Administration (FDA) granted Fast Track designation for investigational TEV-53408, an anti-IL-15 antibody, for the treatment of people with celiac disease on a gluten-free diet. TEV-53408 is currently being evaluated in a Phase 2a trial to assess the efficacy and safety in adults with celiac disease.
In March 2025, Barinthus Biotherapeutics plc (NASDAQ: BRNS) has entered 2025 with a renewed strategic focus on immunological and inflammatory diseases. Following its restructuring, the company is well-positioned to advance its lead asset, VTP-1000, along with the SNAP-TI platform, for the treatment of celiac disease. With innovative design features that enhance antigen targeting, allow intramuscular administration, and potentially improve tolerability, VTP-1000 has the potential to become a leading therapy for the approximately 80 million people worldwide affected by celiac disease.
In February 2025, PhaseV, a leader in software and machine learning (ML) for clinical trial optimization, announced a strategic partnership with Alimentiv Inc., a global gastrointestinal (GI) contract research organization (CRO). This collaboration aims to enhance the design and execution of advanced adaptive clinical trials for various GI conditions, including inflammatory bowel disease (IBD), celiac disease, eosinophilic gastrointestinal disease (EGID), and other related disorders.
In October 2024, Topas Therapeutics reported positive topline results from its Phase IIa trial of TPM502 in celiac disease patients. The findings provide the first clinical proof of concept for the company's proprietary nanoparticle platform, highlighting its potential to induce targeted, antigen-specific tolerogenic effects.
In September 2024, Barinthus Biotherapeutics plc (NASDAQ: BRNS), a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies that direct T cells to manage diseases, has commenced its first-in-human Phase 1 trial of VTP-1000 in adults with celiac disease. This randomized, placebo-controlled study, incorporating a controlled gluten challenge, aims to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of VTP-1000.
In May 2024, Entero Therapeutics, Inc. (previously known as First Wave BioPharma, Inc.) has introduced its new corporate identity and website. This rebranding comes after its recent merger with ImmunogenX and underscores the company's commitment to tackling unmet needs in gastrointestinal health, including celiac disease, a condition that currently lacks approved treatments.
In 2023, the United States represented the largest portion of the celiac disease market among the 7MM, contributing roughly 70% to the overall market.
Among the EU4 and the UK, Italy had the highest market valuation for celiac disease, estimated at around USD 200 million.
At present, a gluten-free diet is the sole effective treatment for celiac disease, with the market in Japan valued at around USD 1,500 million in 2023.
Celiac disease exhibits a significant gender imbalance, primarily affecting females. In Germany, for example, around 60% of diagnosed cases are female.
In 2023, classical celiac disease accounted for approximately 30% of all celiac disease cases in Japan.
According to the Beyond Celiac foundation (2024), approximately 1 in 133 Americans, or around 1% of the population, has celiac disease. It is also estimated that up to 83% of Americans with celiac disease remain undiagnosed or are incorrectly diagnosed with other medical conditions.
According to Stahl et al. (2023), Celiac disease is a prevalent chronic condition globally, with an aggregated prevalence of 1.4%, though it can be significantly higher in specific regions. In a prospective birth cohort study involving infants at risk for celiac disease in Europe and the United States, the incidence was estimated to be 3% in Sweden and 2.4% in Colorado.
According to the Celiac Disease Foundation, celiac disease is a significant autoimmune disorder estimated to impact 1 in 100 people globally. Additionally, 2.5 million Americans remain undiagnosed and are susceptible to potential long-term health issues.
Key Celiac Disease Companies: Sanofi (Provention Bio), Zedira, Dr. Falk Pharma, Takeda, ImmunoGenX, Provention Bio, Sanofi, Topas Therapeutics GmbH, Pfizer, 9 Meters Biopharma, Inc., ChemoCentryx, BioLineRx, Ltd., and others
Key Celiac Disease Therapies: PRV-015, TAK-227/ZED1227, Latiglutenase(IMGX003), Ordesekimab, TAK-101 and Zamaglutenase, TPM502, Ritlecitinib, TAK-062, larazotide acetate, CCX282-B, BL-7010, and others
The Celiac Disease epidemiology based on gender analyzed that, females are affected more than males
The Celiac Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Celiac Disease pipeline products will significantly revolutionize the Celiac Disease market dynamics.
Celiac Disease Overview
Celiac Disease is a chronic autoimmune disorder triggered by the ingestion of gluten, a protein found in wheat, barley, and rye. Celiac Disease causes an immune response that damages the lining of the small intestine, leading to malabsorption of essential nutrients. Celiac Disease affects both children and adults and can present with a wide range of gastrointestinal and non-gastrointestinal symptoms.
Celiac Disease symptoms commonly include abdominal pain, bloating, diarrhea, constipation, fatigue, weight loss, and nutrient deficiencies. Celiac Disease may also manifest through skin rashes, neurological issues, anemia, osteoporosis, and infertility in some individuals. Celiac Disease is strongly associated with genetic factors, particularly the HLA-DQ2 and HLA-DQ8 genes.
Celiac Disease diagnosis involves a combination of serologic testing for specific antibodies and confirmation through a small intestinal biopsy. Celiac Disease management requires a strict lifelong gluten-free diet, which helps in healing the intestinal lining and preventing further complications. Celiac Disease patients must avoid even trace amounts of gluten to maintain health and prevent flare-ups.
Celiac Disease awareness and early detection are crucial to preventing long-term health consequences. Celiac Disease research continues to explore potential therapies beyond dietary management, including enzyme treatments and immune-modulating agents to improve patient outcomes.
Celiac Disease Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Celiac Disease Epidemiology Segmentation:
The Celiac Disease market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Total Prevalent Population of Celiac Disease in the 7MM
Total Diagnosed Prevalent Population of Celiac Disease in the 7MM
Type-specific Prevalent Population of Celiac Disease in the 7MM
Gender-specific Prevalent Population of Celiac Disease in the 7MM
Age-specific Distribution of Celiac Disease in the 7MM
Download the report to understand which factors are driving Celiac Disease epidemiology trends @ Celiac Disease Prevalence
Celiac Disease Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Celiac Disease market or expected to get launched during the study period. The analysis covers Celiac Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Celiac Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Celiac Disease Therapies and Key Companies
PRV-015 : Sanofi (Provention Bio)
TAK-227/ZED1227: Zedira, Dr. Falk Pharma, and Takeda
Latiglutenase(IMGX003): ImmunoGenX
Ordesekimab: Provention Bio/Sanofi
TAK-101 and Zamaglutenase: Takeda
TPM502: Topas Therapeutics GmbH
Ritlecitinib: Pfizer
TAK-062: Takeda
larazotide acetate: 9 Meters Biopharma, Inc.
CCX282- B: ChemoCentryx
BL-7010: BioLineRx, Ltd.
Discover more about therapies set to grab major Celiac Disease market share @ Celiac Disease Treatment Market
Celiac Disease Market Strengths
The pipeline activity of Celiac Disease is quite efficient with the presence of variable key players such as First Wave BioPharma, Sanofi, Takeda, etc., which are efficiently involved in developing milestone treatment options.
Latiglutenase has the potential to be a first to-market treatment for celiac disease, a GIdisorder that impacts approximately three million people in the US and for which no approved pharmacologic treatment currently exists.
Celiac Disease Market Opportunities
Several organizations such as Celiac Disease Foundation, National Celiac Association (NCA), American Celiac Disease Alliance (Celiac Disease A), Coelic UK etc. are actively working to provide information and awareness of the disorder.
There is ongoing research into celiac disease, including potential treatments and therapies. Individuals with celiac disease can contribute to this research by participating in clinical trials or fundraising for research organizations.
Scope of the Celiac Disease Market Report
Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Celiac Disease Companies: Sanofi (Provention Bio), Zedira, Dr. Falk Pharma, Takeda, ImmunoGenX, Provention Bio, Sanofi, Topas Therapeutics GmbH, Pfizer, 9 Meters Biopharma, Inc., ChemoCentryx, BioLineRx, Ltd., and others
Key Celiac Disease Therapies: PRV-015, TAK-227/ZED1227, Latiglutenase(IMGX003), Ordesekimab, TAK-101 and Zamaglutenase, TPM502, Ritlecitinib, TAK-062, larazotide acetate, CCX282-B, BL-7010, and others
Celiac Disease Therapeutic Assessment: Celiac Disease current marketed and Celiac Disease emerging therapies
Celiac Disease Market Dynamics: Celiac Disease market drivers and Celiac Disease market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Celiac Disease Unmet Needs, KOL's views, Analyst's views, Celiac Disease Market Access and Reimbursement
To know more about Celiac Disease companies working in the treatment market, visit @ Celiac Disease Clinical Trials and Therapeutic Assessment
Table of Contents
1. Celiac Disease Market Report Introduction
2. Executive Summary for Celiac Disease
3. SWOT analysis of Celiac Disease
4. Celiac Disease Patient Share (%) Overview at a Glance
5. Celiac Disease Market Overview at a Glance
6. Celiac Disease Disease Background and Overview
7. Celiac Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Celiac Disease
9. Celiac Disease Current Treatment and Medical Practices
10. Celiac Disease Unmet Needs
11. Celiac Disease Emerging Therapies
12. Celiac Disease Market Outlook
13. Country-Wise Celiac Disease Market Analysis (2020–2034)
14. Celiac Disease Market Access and Reimbursement of Therapies
15. Celiac Disease Market Drivers
16. Celiac Disease Market Barriers
17. Celiac Disease Appendix
18. Celiac Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/asco-conference-coverage
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
33 minutes ago
- Globe and Mail
MASH Market Size in the 7MM was ~USD 1.8 billion in 2023, is projected to grow at a CAGR of 24%, estimates DelveInsight
DelveInsight's ' MASH Treatment Market Insights, Epidemiology, and Market Forecast – 2034 ' report delivers an in-depth understanding of MASH, historical and forecasted epidemiology, as well as the MASH market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. Discover which therapies are expected to grab the MASH Market Share @ MASH Market Outlook Key Takeaways from the MASH Market Report In June 2025, Akero Therapeutics Inc. announced a study is to assess the safety and tolerability of EFX compared to placebo in subjects with non-invasively diagnosed NASH/MASH and NAFLD/MASLD. In June 2025, Boehringer Ingelheim conducted a study is to find out whether a medicine called survodutide helps people with MASH and moderate or advanced liver fibrosis improve their liver function. This study is to find out the effect of survodutide on MASH and liver fibrosis. In June 2025, 89bio Inc. organized a study will assess the efficacy and safety of pegozafermin administered in participants with compensated cirrhosis due to MASH (biopsy-confirmed fibrosis stage F4 MASH [previously known as nonalcoholic steatohepatitis, NASH]). According to DelveInsight's estimates, there were ~215 million prevalent cases of MASLD (formerly known as NAFLD) in the 7MM in 2023, including ~30 million prevalent cases of MASH. Of the total MASH cases, ~8 million were diagnosed in the 7MM. Among the 7MM, the US had the highest number of MASH Diagnosed Prevalent Cases, with ~4 million cases in 2023, a figure projected to increase by 2034. In 2023, EU4 and the UK accounted for ~3 million MASH diagnosed prevalent cases with Germany having the highest at ~780 thousand cases, followed by Italy with ~615 thousand cases. In contrast, Spain had the least, with ~340 thousand cases. In 2023, the UK had ~480 thousand MASH Diagnosed Prevalent Cases. In 2023, Japan recorded ~670 thousand MASH diagnosed prevalent cases, a number expected to rise by 2034. In 2023, the US had the following severity-specific diagnosed prevalent cases of MASH: ~880 thousand cases at the F0 stage, ~1,610 thousand at the F1 stage, ~880 thousand at the F2 stage, ~510 thousand at the F3 stage, and ~340 thousand at the F4 stage. The leading MASH Companies such as 89bio, Inc., Akero Therapeutics, Galectin Therapeutics, Viking Therapeutics, Novo Nordisk A/S, Inventiva, and others. Promising MASH Pipeline Therapies such as TVB-2640, Survodutide, Miricorilant (Cohort B), Efimosfermin, Pegozafermin, DD01, ALG-055009, and others. Stay ahead in the MASH Therapeutics Market with DelveInsight's Strategic Report @ MASH Treatment Market MASH Epidemiology Segmentation in the 7MM Total MASH Prevalent Cases Total MASH Prevalent Cases Total Diagnosed Prevalent Cases MASH Severity-specific Diagnosed Prevalent Cases Download the report to understand which factors are driving MASH Epidemiology trends @ MASH Prevalence MASH Marketed Drugs REZDIFFRA (resmetirom): Madrigal Pharmaceuticals REZDIFFRA (resmetirom), a Thyroid Hormone Receptor-beta (THR-ß) agonist, is approved for treating adults with noncirrhotic MASH and moderate to advanced liver fibrosis (F2-F3), in conjunction with diet and exercise. It received accelerated approval due to improvements in MASH and fibrosis. In March 2024, the US FDA approved REZDIFFRA for adults with noncirrhotic MASH with moderate to advanced liver fibrosis (F2 to F3). MASH Emerging Drugs Efruxifermin (EFX): Akero Therapeutics Efruxifermin (EFX), Akero Therapeutics' leading candidate for MASH, is an engineered Fc-FGF21 fusion protein mimicking the biological activity of native FGF21. EFX has shown promise in reducing liver fat, inflammation, and fibrosis, while enhancing insulin sensitivity and lipid metabolism. It offers once-weekly dosing and a favorable tolerability profile in clinical trials. Currently, EFX is being evaluated in three Phase III studies, with encouraging results from Phase II trials showing its potential to reverse fibrosis and improve liver function. The Phase III SYNCHRONY study is expected to provide results in 2026. VK2809 (TRß Agonist): Viking Therapeutics VK2809 is an orally available, liver-targeted agonist of the Thyroid Hormone Beta Receptor (TRß), designed to specifically modulate lipid metabolism. By selectively activating TRß in liver tissue, VK2809 aims to improve cholesterol and lipoprotein levels through the upregulation of genes involved in lipid clearance. The compound has shown significant therapeutic potential in lipid disorders, meeting both primary and secondary endpoints in the Phase IIb VOYAGE study for patients with NASH/MASH and fibrosis, as well as in a Phase IIa study for patients with elevated LDL-C and MASLD. Efimosfermin alfa (formerly BOS-580): Boston Pharmaceuticals Efimosfermin alfa (BOS-580), developed by Boston Pharmaceuticals, is a long-acting variant of FGF21 designed to regulate metabolic pathways, reducing liver fat, inflammation, and fibrosis in MASH patients. Manufactured in mammalian cells for human-like glycosylation, it is administered as a once-monthly subcutaneous injection. BOS-580 is currently undergoing Phase II trials for MASH treatment. In September 2020, Boston Pharmaceuticals licensed the genetically engineered FGF21 variant from Novartis, positioning it as a potential best-in-class treatment for MASH. To learn more about MASH Treatment guidelines, visit @ MASH Clinical Trials Assessment MASH Companies 89bio, Inc., Akero Therapeutics, Galectin Therapeutics, Viking Therapeutics, Novo Nordisk A/S, Inventiva, and others. MASH Drugs Market Insights Efruxifermin (EFX) is an investigational Fc-FGF21 fusion protein developed by Akero Therapeutics for the treatment of MASH. Designed to mimic the biological activity of FGF21, EFX aims to address key drivers of MASH by reducing liver fat and inflammation, reversing fibrosis, and improving insulin sensitivity and lipid metabolism. In a 96-week Phase IIb study, 39% of patients with compensated cirrhosis due to MASH experienced a reversal of cirrhosis without worsening of the disease, compared to 15% in the placebo group. These promising results have led to the initiation of the Phase III SYNCHRONY clinical program, which includes trials evaluating EFX in patients with pre-cirrhotic MASH (F2-F3 fibrosis) and those with compensated cirrhosis (F4) due to MASH. MASH Treatment Market The MASH treatment landscape is rapidly evolving, particularly with the USFDA's accelerated approval of Madrigal's REZDIFFRA, now considered a key therapy for patients with moderate to advanced liver fibrosis. This selective thyroid hormone receptor-beta agonist has shifted the approach from invasive liver biopsies to non-invasive diagnostic methods, improving patient access to treatment. The landscape is further shaped by a diverse pipeline of therapies targeting various mechanisms, such as FXR agonists, PPAR modulators, and GLP-1 receptor agonists, with clinical trials exploring combination therapies to address the complex nature of the disease. As researchers focus on personalized medicine and better patient stratification, the priority remains refining treatment strategies while navigating challenges in trial recruitment and regulatory requirements. The combination of emerging therapies and existing lifestyle interventions continues to influence clinical practice in managing MASH/NASH. Scope of the MASH Market Report Coverage- 7MM Study Period- 2020-2034 MASH Companies- 89bio, Inc., Akero Therapeutics, Galectin Therapeutics, Viking Therapeutics, Novo Nordisk A/S, Inventiva, and others. MASH Pipeline Therapies- TVB-2640, Survodutide, Miricorilant (Cohort B), Efimosfermin, Pegozafermin, DD01, ALG-055009, and others. MASH Market Dynamics: MASH Market Drivers and Barriers MASH Market Access and Reimbursement, Unmet Needs and Future Perspectives Table of Contents 1. Key Insights 2. MASH Market Report Introduction 3. MASH Market Overview at a Glance 4. Methodology of Epidemiology and Market 5. Executive Summary 6. Key Events 7. Disease Background and Overview 8. MASH Epidemiology and Patient Population 9. Patient Journey 10. MASH Marketed Drugs 11. MASH Emerging Drugs 12. MASH – 7MM Market Analysis 13. Key Opinion Leaders' Views 14. MASH Unmet Needs 15. MASH SWOT Analysis 16. MASH Market Access and Reimbursement 17. Appendix 18. DelveInsight Capabilities 19. Disclaimer 20. About DelveInsight About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Globe and Mail
an hour ago
- Globe and Mail
Obesity Drugs Market 2034: Clinical trials, EMA, PDMA, FDA Approvals, Medication, Statistics, Revenue, Therapies, Prevalence and Companies by DelveInsight
"Obesity Drugs Market" Obesity Companies such as Yuhan, Click Therapeutics, Novo Nordisk, ProQR Therapeutics, Bukwang Pharmaceutical, Empros Pharma, Boehringer Ingelhium, Rhythm Pharmaceuticals, BioRestorative Therapies, Hanmi Pharmaceuticals, Carmot Therapeutics, D&D Pharmatech, SCOHIA PHARMA, Nano Precision Medical, Terns Pharmaceuticals, Caliway Biopharmaceutics, Eli Lilly and Company, and others (Albany, USA) DelveInsight's 'Obesity Market Insights, Epidemiology, and Market Forecast-2034' report delivers an in-depth understanding of Obesity, historical and forecasted epidemiology as well as the Obesity market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Obesity market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Obesity market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Obesity treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Obesity market. Request for a Free Sample Report @ Obesity Market Forecast Some facts of the Obesity Market Report are: In March 2025, Novo Nordisk launched NovoCare® Pharmacy, a direct-to-patient delivery service, to ensure access to Wegovy® (semaglutide) injection in all dose strengths (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg). This service offers uninsured patients or those with commercial insurance lacking obesity medicine coverage the option to purchase Wegovy® at a reduced cost of $499 per month. This initiative expands Novo Nordisk's efforts to meet the needs of individuals living with obesity, following the FDA's confirmation that the shortage of the medication has been resolved and that all doses now meet or exceed U.S. demand. In February 2025, Eli Lilly launched 7.5 mg and 10 mg Zepbound (tirzepatide) vials for $499 through the Zepbound Self Pay Journey Program, alongside price reductions for 2.5 mg and 5 mg vials. These are available exclusively via LillyDirect Self Pay Pharmacy Solutions, offering direct savings outside of insurance. In February 2025, Amgen announced that the U.S. FDA has placed a hold on a study of the company's early-stage obesity candidate, AMG 513, marking another potential setback in its efforts to enter the growing weight loss drug market. Amgen has provided limited information about the drug, including its mechanism of action. In January 2025, Novo Nordisk reported that a high dose of its obesity drug Wegovy led to greater weight loss than the approved regimen in a Phase III trial. However, the data also suggest that Eli Lilly's rival GLP-1 drug Zepbound may still have an advantage over Wegovy. In January 2025, Verdiva Bio Limited launched as a clinical-stage biopharmaceutical company focused on innovative therapies for obesity and cardiometabolic disorders. The company is advancing next-generation oral and injectable treatments and raised $411M in an oversubscribed Series A round, co-led by Forbion and General Atlantic, with participation from RA Capital Management, OrbiMed, Logos Capital, Lilly Asia Ventures, and LYFE Capital. In January 2025, Eli Lilly filed a motion to intervene as a defendant in a case between the Outsourcing Facilities Association and FarmaKeio Custom Compounding against the FDA. The court has ordered the Outsourcing Facilities Association to respond by January 15, with Eli Lilly's reply due by January 21. As per DelveInsight's estimates, the United States accounted for the highest number of total prevalent cases of Obesity among the 7MM in 2023. DelveInsight's consultant estimates that adult patients constituted the maximum number of cases of obesity patients seeking help in 2023. According to the findings, treatment rate for children was found to be less than that of adults across countries. Among EU4 and the UK, the highest number of treated cases of obesity in adults was observed in the United Kingdom in 2023, which is followed by Germany. The leading Obesity Companies such as Rhythm Pharmaceuticals, Boehringer Ingelhium, D&D Pharmatech, ProQR Therapeutics, Nano Precision Medical, Bukwang Pharmaceutical, Caliway Biopharmaceutics, Yuhan, Terns Pharmaceuticals, BioRestorative Therapies, SCOHIA PHARMA, Click Therapeutics, Hanmi Pharmaceuticals, Novo Nordisk, Empros Pharma, Carmot Therapeutics, Eli Lilly and Company, and others Promising Obesity Therapies such as IMCIVREE (setmelanotide), ZEPBOUND (tirzepatide), Semaglutide oral, Survodutide (BI 456906), DD03, AX-0601, NPM 139, BK-1701, CBW-520, YH34160, TERN-601, Thermostem, SCO-267, CT-181, HM15136, NNC0480-0389, EMP-16, CT-868, Semaglutide, and others. On June 2023, Eli Lilly and Company (NYSE: LLY) announced the new phase 2 data from retatrutide, Lilly's investigational molecule being studied for the treatment of obesity. At 24 weeks, retatrutide (1 mg, 4 mg, 8 mg or 12 mg) met the primary endpoint for the efficacy estimand in participants living with obesity or overweight without diabetes, demonstrating a mean weight reduction up to 17.5% (41.2 lb. or 18.7 kg). In a secondary endpoint, retatrutide demonstrated a mean weight reduction up to 24.2% (57.8 lb. or 26.2 kg)ii at the end of the 48-week treatment duration. On June 2023, Pfizer (NYSE: PFE) updated that it is scrapping its once-a-day experimental obesity pill because of concerns about liver safety, but will continue developing its other obesity pill, the twice-daily treatment danuglipron, as it races to rival the success of other weight loss treatments. On May 2023, Novo Nordisk (NYSE: NVO) announced positive results from a phase IIIa study, OASIS 1, in the global OASIS program for a once-daily oral formulation of semaglutide in obesity. Obesity Overview Obesity is a chronic condition characterized by an excessive accumulation of body fat, leading to adverse health effects and increased risk of various diseases. It is typically defined by a body mass index (BMI) of 30 or higher. Obesity results from complex interactions between genetic, environmental, socioeconomic, and behavioral factors. Sedentary lifestyles, high-calorie diets, and genetic predispositions contribute to its development. Obesity is associated with numerous health complications, including type 2 diabetes, cardiovascular disease, hypertension, certain cancers, and musculoskeletal disorders. Additionally, it can impair quality of life and increase mortality rates. Prevention and management strategies for obesity include dietary modifications, regular physical activity, behavioral therapy, medications, and in severe cases, bariatric surgery. Public health initiatives and policies aimed at promoting healthy lifestyles and reducing obesity prevalence are essential to address this global epidemic and its associated health burdens. Learn more about Obesity treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Obesity Market The Obesity market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Obesity market trends by analyzing the impact of current Obesity therapies on the market and unmet needs, and drivers, barriers, and demand for better technology. This segment gives a thorough detail of the Obesity market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Obesity market data are presented with relevant tables and graphs to give a clear view of the market at first sight. According to DelveInsight, the Obesity market in 7MM is expected to witness a major change in the study period 2020-2034. Obesity Epidemiology The Obesity epidemiology section provides insights into the historical and current Obesity patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Obesity market report also provides the diagnosed patient pool, trends, and assumptions. Explore more about Obesity Epidemiology @ Obesity Market Dynamics Obesity Drugs Uptake This section focuses on the uptake rate of the potential Obesity drugs recently launched in the Obesity market or expected to be launched in 2020-2034. The analysis covers the Obesity market uptake by drugs, patient uptake by therapies, and sales of each drug. Obesity Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Obesity market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions. Obesity Pipeline Development Activities The Obesity report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Obesity key players involved in developing targeted therapeutics. Request for a sample report to understand more about the Obesity pipeline development activities @ Obesity Medication and Approved drugs Obesity Therapeutics Assessment Major key companies are working proactively in the Obesity Therapeutics market to develop novel therapies which will drive the Obesity treatment markets in the upcoming years are Novo Nordisk, Eli Lilly and Company, MedImmune, Boehringer Ingelheim, Raziel Therapeutics, Altimmune, Saniona, YSOPIA Bioscience, Innovent Biologics, Glaceum, Shionogi, Aardvark Therapeutics, NuSirt Biopharma, Novartis, CSPC Baike (Shandong) Biopharmaceutical, Jiangsu HengRui Medicine, Carmot Therapeutics, Pfizer, Sciwind Biosciences, Empros Pharma and others. Learn more about the emerging Obesity therapies & key companies @ Obesity Clinical Trials and Advancements Obesity Report Key Insights 1. Obesity Patient Population 2. Obesity Market Size and Trends 3. Key Cross Competition in the Obesity Market 4. Obesity Market Dynamics (Key Drivers and Barriers) 5. Obesity Market Opportunities 6. Obesity Therapeutic Approaches 7. Obesity Pipeline Analysis 8. Obesity Current Treatment Practices/Algorithm 9. Impact of Emerging Therapies on the Obesity Market Table of Contents 1. Key Insights 2. Executive Summary 3. Obesity Competitive Intelligence Analysis 4. Obesity Market Overview at a Glance 5. Obesity Disease Background and Overview 6. Obesity Patient Journey 7. Obesity Epidemiology and Patient Population 8. Obesity Treatment Algorithm, Current Treatment, and Medical Practices 9. Obesity Unmet Needs 10. Key Endpoints of Obesity Treatment 11. Obesity Marketed Products 12. Obesity Emerging Therapies 13. Obesity Seven Major Market Analysis 14. Attribute Analysis 15. Obesity Market Outlook (7 major markets) 16. Obesity Access and Reimbursement Overview 17. KOL Views on the Obesity Market 18. Obesity Market Drivers 19. Obesity Market Barriers 20. Appendix 21. DelveInsight Capabilities 22. Disclaimer About DelveInsight DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector. Media Contact Company Name:DelveInsight Business Research LLP Contact Person: Ankit Nigam Email:Send Email Phone: +14699457679 Address:304 S. Jones Blvd #2432 City: Albany State: New York Country: United States Website: Press Release Distributed by To view the original version on ABNewswire visit: Obesity Drugs Market 2034: Clinical trials, EMA, PDMA, FDA Approvals, Medication, Statistics, Revenue, Therapies, Prevalence and Companies by DelveInsight
Globe and Mail
4 hours ago
- Globe and Mail
Postpartum Depression Treatment Market Size in the 7MM was estimated to be USD 260 million in 2023, and is expected to increase a significant CAGR by 2034, estimates DelveInsight
DelveInsight's 'Postpartum Depression Treatment Market Insights, Epidemiology, and Market Forecast – 2034' report delivers an in-depth understanding of all Postpartum Depression types, historical and forecasted epidemiology as well as the Postpartum Depression market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan. Discover which therapies are expected to grab the Postpartum Depression Market Share @ Postpartum Depression Market Outlook Key Takeaways from the Postpartum Depression Market Report In May 2025, Nanjing Minova Pharmaceutical Co., Ltd. announced a study is a multicenter, randomized, double-blind, placebo-controlled trial. It includes three groups. Each group will enroll 24 participants. The trial aims todetermine： To evaluate the efficacy of MI078 capsules in treating postpartum depression and to explore the optimal dosing regimen for MI078 capsules. In May 2025, Reunion Neuroscience Inc. announced a study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms in participants with moderate-to-severe postpartum depression (PPD) as compared to active-placebo. In the seven major Postpartum Depression Therapeutics Market, SNRI's and SSRI's constituted 20% market share of the overall Postpartum Depression Drugs Market, while Atypical antidepressants and Antipsychotics held 19% market share, in 2023. In the 7MM, ZURZUVAE is expected to garner Postpartum Depression Therapeutics market revenue of ~USD 600 million by 2034. Among the seven major market, the United States held the highest Postpartum Depression Drugs Market Share (64%) of the overall Postpartum Depression market. Among EU4 and the UK, the UK accounted for the highest Postpartum Depression Treatment Market Size was ~USD 25 million in 2023 Japan accounted for a Postpartum Depression Market Size of ~USD 20 million in 2023, which is expected to increase at a moderate rate by 2034. The leading Postpartum Depression Companies such as Sage Therapeutics, Biogen, Marinus Pharmaceuticals, Lipocine, Brii Biosciences Limited and others. Promising Postpartum Depression Pipeline Therapies such as SAGE-217, Brexanolone, Aripiprazole, Escitalopram, ZULRESSO®, BRII-296, Ganaxolone, Sertraline and others. Stay ahead in the Postpartum Depression Therapeutics Market with DelveInsight's Strategic Report @ Postpartum Depression Treatment Market Postpartum Depression Epidemiology Total Diagnosed Prevalent Population of Maternal Postpartum Depression Download the report to understand which factors are driving Postpartum Depression Epidemiology trends @ Postpartum Depression Prevalence Postpartum Depression Marketed Therapies ZURZUVAE (zuranolone) : Sage Therapeutics/Biogen Zuranolone (SAGE-217) is an investigational, oral, novel medicine in development for postpartum depression (PPD). It is given once daily, a 2-week therapy neuroactive steroid (NAS) GABAA receptor positive allosteric modulator (PAM) specifically designed to relieve several depression disorders, including PPD, major depressive disorder (MDD), and treatment-resistant depression. The GABA system is the major inhibitory signaling pathway of the brain, and the central nervous system (CNS) significantly regulates CNS function. SAGE-217 has been optimized for selectivity to synaptic and extrasynaptic type a γ-aminobutyric acid (GABAA) receptors and a pharmacokinetic profile for daily oral dosing. ZULRESSO: Sage Therapeutics ZULRESSO is a proprietary IV formulation of brexanolone. Brexanolone is chemically identical to allopregnanolone, a naturally occurring neuroactive steroid that acts as a positive allosteric modulator of gamma-aminobutyric acid (GABA) receptors indicated for treating PPD in adults. Brexanolone is available to patients only through a Risk Evaluation and Mitigation Strategy (REMS) program and must be administered at a certified healthcare facility. In addition, patients must be monitored continuously during the drug infusion due to the risk of serious side effects. Notably, ZULRESSO (brexanolone) is the first drug approved by the US FDA specifically for PPD in adults. Postpartum Depression Emerging Therapies Ganaxolone: Marinus Pharmaceuticals Ganaxolone (CCD-1042) is a lead clinical-stage drug candidate that brings a GABAA receptor modulating mechanism and an extensive safety database with exhibited anti-epileptic (antiseizure), anxiolytic (anti-anxiety) and anti-depressive activity in development by Marinus Pharmaceuticals. It is being developed in three different dosage forms (IV, capsule, and liquid) to maximize therapeutic reach to adult and pediatric patients in acute and chronic care settings with severe PPD. Unlike benzodiazepines, ganaxolone exhibits antiseizure and anti-anxiety activity via its effects on synaptic and extrasynaptic GABAA receptors. Ganaxolone has been designed with an added methyl group that prevents back conversion to an active steroid, which unlocks ganaxolone's potential for chronic use. In preclinical studies, ganaxolone exhibited potency and efficacy comparable to allopregnanolone. To learn more about Postpartum Depression Treatment guidelines, visit @ Postpartum Depression Clinical Trials Assessment Postpartum Depression Market Outlook Antidepressants, such as Abilify (aripiprazole), Zoloft (sertraline hydrochloride), Spravato (esketamine), Prozac (fluoxetine capsules), Celexa (citalopram hydrobromide), Luvox CR (Fluvoxamine Maleate), and Paxil CR (paroxetine) form the mainstay in the Postpartum Depression treatment. Although these drugs are approved for treating depression-related disorders such as major depressive disorder (MDD), obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), treatment-resistant depression (TRD), etc., they are being used as off-label drugs for the treatment of PPD. The type of medication prescribed by the doctors largely depends on the set of symptoms, severity and the specific type of PPD the patient is suffering from. The primary concern about antidepressants is the uncertainty in the outcomes and their side effects on new born due to breastfeeding. Though antidepressants are not necessarily a permanent cure for PPD, they are an important aspect of managing depression symptoms and restoring quality of life. Postpartum Depression Treatment Landscape Antidepressant medications, cognitive-behavioral therapy (CBT), and interpersonal therapy are effective in treating Postpartum Depression. Other Postpartum Depression treatments which may be useful include psychodynamic therapy, light therapy, exercise, and yoga, but the current research evidence about the efficacy of such treatment regimens is more preliminary. Scope of the Postpartum Depression Market Report Coverage- 7MM Study Period- 2020-2034 Postpartum Depression Companies- Sage Therapeutics, Biogen, Marinus Pharmaceuticals, Lipocine, Brii Biosciences Limited and others. Postpartum Depression Pipeline Therapies- SAGE-217, Brexanolone, Aripiprazole, Escitalopram, ZULRESSO®, BRII-296, Ganaxolone, Sertraline and others. Postpartum Depression Market Dynamics: Postpartum Depression Market Drivers and Barriers Postpartum Depression Market Access and Reimbursement, Unmet Needs and Future Perspectives Table of Content 1. Key Insights 2. Report Introduction 3. Postpartum Depression Market Overview at a Glance 4 Executive Summary of Postpartum Depression 5 Key events 6 Disease Background and Overview 7 Treatment and Management 8 Methodology 9 Epidemiology and Patient Population 10 Patient Journey 11 Marketed Therapies 12 Emerging Therapies 13 Postpartum Depression (PPD): Seven Major Market Analysis 14 KOL Views 15 SWOT Analysis 16 Unmet Needs 17 Market Access and Reimbursement 18 Appendix 19 DelveInsight Capabilities 20 Disclaimer 21 About DelveInsight About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
